A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

NCT00403052 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Administrative reasons

Conditions

Colorectal Neoplasms

Interventions

DRUG: 1018 ISS immunostimulatory oligonucleotide

Sponsor

Dynavax Technologies Corporation